Ensign Peak Advisors, Inc Immuno Gen, Inc. Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $4.08 Million - $5.75 Million	289,275 Added 49.31%	875,868 $13.9 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $2.2 Million - $11.8 Million	586,593 New	586,593 $11.1 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.17 Million - $1.69 Million	261,756 Added 653.25%	301,826 $1.44 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $30,544 - $53,631	7,170 Added 21.79%	40,070 $191,000
Q4 2021 Feb 11, 2022	BUY	$4.75 - $7.5 $156,275 - $246,750	32,900 New	32,900 $244,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.